trial

A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

NCTId NCT06649214
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 654 (estimated)
Sponsored by Qilu Pharmaceutical Co., Ltd.
Primary completion 2026-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
654 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-11
Primary completion
2026-04
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Qilu Pharmaceutical Co., Ltd.Lead Sponsor

Sites

0 total

Linked catalysts

1
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia — primary completion2026-04

Facts & assertions

4 sourced
Enrollment
654
Phase
PHASE3
Primary Completion Date
2026-04
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Qilu Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication